Development of a safe vaccine to halt the HIV-1 epidemic is an urgent global public health priority. Our Seattle vaccine unit and community have devoted more than 17 years to clinical HIV vaccine development. Our accomplishments include long-standing leadership with the HVTN, an outstanding track record in volunteer enrollment and retention in phase l-lll vaccine trials, and extensive mentorship to new vaccine investigators. In this application, we renew our overall goal to accelerate HIV vaccine development by joining the HIV Vaccine Trials Network (HVTN) as a single comprehensive clinical vaccine trials unit. We propose four specific aims to accomplish our goals:
In Aim 1, we will provide the administrative infrastructure to conduct high quality clinical HIV vaccine research and evaluation.
In Aim 2, we will contribute scientific leadership and clinical research expertise to advance HIV vaccine development through the HVTN.
In Aim 3, we will partner with the Seattle community to enhance communication, education, outreach and recruitment for the successful implementation of HIV vaccine clinical research.
In Aim 4, we will execute phase l-lll HIV vaccine clinical trials in accordance with Good Clinical Practice. We recognize that many obstacles remain in developing a successful HIV-1 vaccine, and the Seattle HVTU will continue its commitment to seek a long-term solution to the HIV-1 epidemic. ADMINISTRATIVE COMPONENT:
|La Rosa, Alberto M; Harrison, Linda J; Taiwo, Babafemi et al. (2016) Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 3:e247-58|
|Grant, Philip M; Kitch, Douglas; McComsey, Grace A et al. (2016) Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS 30:2805-2813|
|Weinberg, Adriana; Park, Jeong-Gun; Bosch, Ronald et al. (2016) Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. J Acquir Immune Defic Syndr 71:137-45|
|Grant, Philip M; Kitch, Douglas; McComsey, Grace A et al. (2016) Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals. J Infect Dis 214:607-11|
|Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60|
|Astronomo, Rena D; Santra, Sampa; Ballweber-Fleming, Lamar et al. (2016) Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine 14:97-111|
|Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-NaÃ¯ve Men and Women in the United States. AIDS Behav 20:2983-2995|
|Schoofs, Till; Klein, Florian; Braunschweig, Malte et al. (2016) HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352:997-1001|
|De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80|
|Robertson, K; Jiang, H; Evans, S R et al. (2016) International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol 22:472-8|
Showing the most recent 10 out of 39 publications